Jump Financial LLC Acquires 476,900 Shares of DexCom, Inc. $DXCM

Key Points

• Jump Financial LLC increased its stake in DexCom, Inc. by a staggering 3,927.0% in Q1, acquiring an additional 476,900 shares to reach a total of 489,044 shares.
• DexCom reported earnings of $0.48 per share, exceeding analysts' expectations of $0.45, along with quarterly revenue of $1.16 billion, marking a 15.2% increase year-over-year.
• Multiple brokerages have recently raised their target prices for DexCom, with estimates now ranging from $99.00 to $102.00, reflecting a strong market outlook.

Jump Financial LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3,927.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 489,044 shares of the medical device company's stock after acquiring an additional 476,900 shares during the quarter. DexCom makes up 0.5% of Jump Financial LLC's portfolio, making the stock its 20th largest holding. Jump Financial LLC owned 0.12% of DexCom worth $33,397,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Golden State Wealth Management LLC boosted its stake in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of DexCom during the 1st quarter worth $27,000. Optiver Holding B.V. purchased a new position in shares of DexCom during the 4th quarter worth $33,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth $38,000. Finally, Alpine Bank Wealth Management purchased a new position in shares of DexCom during the 1st quarter worth $40,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. The trade was a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,722 shares of company stock worth $1,306,131 in the last quarter. 0.32% of the stock is owned by company insiders.

DexCom Price Performance

DXCM stock traded up $0.26 during mid-day trading on Wednesday, hitting $76.38. The company had a trading volume of 4,526,376 shares, compared to its average volume of 3,903,861. The company has a market capitalization of $29.95 billion, a price-to-earnings ratio of 53.04, a P/E/G ratio of 1.59 and a beta of 1.43. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $82.56 and a 200 day moving average price of $79.66.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several analyst reports. Argus initiated coverage on shares of DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 price target on the stock. Barclays lifted their target price on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 30th. UBS Group lifted their target price on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Mizuho lifted their target price on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $106.00 target price on shares of DexCom in a research note on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.